Janus Henderson Group PLC Schedule 13G passive stakes

Janus Henderson Group plc and its affiliate Janus Henderson Venture Fund have reported an increased beneficial ownership in ASURE SOFTWARE INC's Class A Common Stock, reaching 6.1% of the class.

Janus Henderson Group plc has reported a 6.6% beneficial ownership stake in Revvity, Inc., holding over 7.6 million American Depositary Shares.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a beneficial ownership of 6.8% in SS&C Technologies Holdings, Inc. common stock.

Janus Henderson Group plc has disclosed a 6.9% beneficial ownership in Sensata Technologies Holding PLC, holding over 10 million ordinary shares.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 7.0% beneficial ownership stake in Flex Ltd. as of September 30, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 7.0% beneficial ownership stake in Gildan Activewear Inc.'s common stock.

Janus Henderson Group plc has reported an increased beneficial ownership of 7.3% in IDEAYA BIOSCIENCES, INC. common stock, totaling 6,428,339 shares.

Janus Henderson Group plc has reported an increased beneficial ownership of 7.7% in Avadel Pharmaceuticals PLC common stock.

Janus Henderson Group plc reports an increased beneficial ownership of 7.7% in Structure Therapeutics Inc. through American Depositary Shares.

Janus Henderson Group plc has reported an increased beneficial ownership of 7.9% in Akero Therapeutics, Inc., holding 6,280,305 ordinary shares.

Janus Henderson Group plc has filed an amendment to its beneficial ownership in Madrigal Pharmaceuticals, Inc., reporting an 8.3% stake in the company's common stock.

Janus Henderson Group plc has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 8.4% in Ziff Davis, Inc. common stock.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 4.8% beneficial ownership in Liberty Media Corporation's Series C Liberty Formula One Common Stock.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 9.8% beneficial ownership stake in Lantheus Holdings, Inc. common stock.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 10.0% beneficial ownership stake in Mirum Pharmaceuticals, Inc. common stock.

Janus Henderson Group plc has reported an increased beneficial ownership in Vaxcyte, Inc. common stock, now holding 10.1% of the class as of September 30, 2025.

Janus Henderson Group plc and its affiliate Janus Henderson Contrarian Fund reported a combined beneficial ownership of 10.2% in Surgery Partners, Inc. common stock.

Janus Henderson Group plc and its affiliates have reported an increased beneficial ownership of 10.2% in Mereo BioPharma Group PLC's American Depositary Shares.

Janus Henderson Group plc has increased its beneficial ownership in Dyne Therapeutics Inc. to 10.4% of common stock, holding 14,745,505 shares.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 10.7% beneficial ownership stake in Avidity Biosciences, Inc.

Janus Henderson Group plc and its affiliate funds have reported an 11.0% beneficial ownership in Protara Therapeutics, Inc. common stock.

Janus Henderson Group plc has filed an amendment to its Schedule 13G, reporting an increased beneficial ownership of 11.4% in Soleno Therapeutics, Inc. as of September 30, 2025.

Janus Henderson Group PLC and its affiliates reported a 12.1% beneficial ownership stake in INVIVYD, INC. common stock as of September 30, 2025.

Janus Henderson Group plc and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 12.3% in Praxis Precision Medicines, Inc. common stock as of September 30, 2025.

Janus Henderson Group PLC and its affiliates reported a significant beneficial ownership stake of 13.1% in Consensus Cloud Solutions, Inc. common stock.

Janus Henderson Group plc and its affiliates reported an increased beneficial ownership of 13.7% in CIMPRESS PLC common stock, totaling 3,340,849 shares.

Janus Henderson Group plc has filed an Amendment No. 8 to Schedule 13G, reporting a 7.8% beneficial ownership stake in Ascendis Pharma A/S.

Janus Henderson Group plc and its affiliates have reported a 6.2% beneficial ownership stake in INOVIO Pharmaceuticals, Inc. common stock.

Janus Henderson Group plc has reported a 5.1% beneficial ownership stake in METSERA, INC., holding over 5.3 million shares.

Janus Henderson Group plc has reported a 5.1% beneficial ownership stake in XENON PHARMACEUTICALS INC. common stock.